Antiglaucoma carbonic anhydrase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 6, 2013, Pages 705-716

  Masini, Emanuela ^a   Carta, Fabrizio ^a   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetazolamide; Brinzolamide; Dichlorophenamide; Dithiocarbamate; Dorzolamide; Glaucoma, carbonic anhydrase inhibitor; Prostaglandin F2 analog; Sulfamate; Sulfamide; Sulfonamide

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; ACETAZOLAMIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; METHAZOLAMIDE;

BITTER TASTE; BLURRED VISION; DRUG EFFICACY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SOLUTION; EYE BURN; EYE REDNESS; GLAUCOMA; HUMAN; OCULAR PRURITUS; REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT;

ANIMALS; AQUEOUS HUMOR; BICARBONATES; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PATENTS AS TOPIC; SULFONAMIDES;

EID: 84878083885     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.794788     Document Type: Review

References (109)

1. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal disease and glaucoma. Nature Rev Drug Discov 2012;11:541-59
2. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Patents 2012;22:79-88
3. Quigley HA. Glaucoma. Lancet 2011;377:1367-77
4. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:151-6
5. Mincione F, Menabuoni L, Supuran CT. Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase-its inhibitors and activators. CRC Press, Boca Raton (FL); 2004 p. 243-54
6. Mincione F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors as ophthalmologic drugs. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken; 2009 p. 139-54
7. Supuran C, Benedini F, Biondi S, et al. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
8. Chong W, Kwan M, Nukui S. 1-[4-(Sulfonyl)-phenyl]-5-benzyl-1H, 1,2,4-triazole derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension. WO075152; 2008
9. Sinha S, Bhat SS, Heidelbaugh TM, et al. Heterocyclic substituted fused carbocycles useful in the treatment of conditions such as glaucoma. WO023758; 2009
10. Ruckmick S, Cain R, Abreo MJ, et al. Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension. WO050615; 2007
11. McIntire GL, Davio SR, Harms AE, et al. Complexes comprising alpha-2-adrenergic receptor agonists and methods of providing neuroprotection or treating or inhibiting progression of glaucoma. US0183946; 2011
12. Old DW. Pyrrolidinones for the treatment of glaucoma and ocular hypertension. WO005176; 2007
13. Burk RM. Novel sulfonamides. WO024611; 2007
14. Woodward DF, Chen J. EP2 receptor agonists for treating glaucoma. WO027468; 2007
15. Prasanna G, Bosworth CF, La Fontaine JA. EP2 agonists. WO015517; 2008
16. Holoboski M, Burk RM, Posner MF. Therapeutic compounds. WO073752; 2008
17. Old DW. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure. WO144623; 2008
18. Dinh DT, Old DW, Burk RM. Therapeutic beta-lactams. WO091764; 2009
19. Maxey KM, Stanton ML. Internal 1,15-lactones of fluprostenol and related prostaglandin F2A analogs and their use in the treatment of glaucoma and intraocular hypertension. US0146821; 2008
20. Woodward DF, Burk RM. Novel prostamides for the treatment of glaucoma and related diseases. US0112058; 2007
21. Bakhit PG, Graham R, Olejnik O. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia. US0244051; 2007
22. Johnson BA, Old DW, Donde Y, et al. Therapeutic compounds. US0186885; 2009
23. Reunamaki T, Pellinen P, Oksala O, et al. Method and composition for treating ocular hypertension and glaucoma. US0152264; 2011
24. Hellberg MR, Namil A, Feng Z, et al. Phenylethylamine analogs and their use for treating glaucoma. WO038372; 2007
25. Dantanarayana AP, May JA. Substituted furo[2,3-G]indazoles for the treatment of glaucoma. US0012291; 2009
26. Abdulrazik M. Novel compounds for the treatment of glaucoma or ocular hypertension. US0305710, 2011
27. Borriello M, Pucci S, Stasi LP, et al. Cyclic amide derivatives as EP4 receptor antagonists. WO004291; 2013
28. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575-600
29. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168-81
30. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
31. Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010;16:3233-45
32. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
33. Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008-2011). Expert Opin Ther Pat 2012;22:903-15
34. Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patents 2006;16:1627-64
35. Aggarwal M, Boone CD, Kondeti B, et al. Structural annotation of human carbonic anhydrases. J Enzyme Inhib Med Chem 2013;28:267-77
36. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68
37. Hewitson KS, Supuran CT. Carbonic anhydrase inhibitors for treating dandruff and related disorders. WO061185; 2010
38. Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO139678; 2010
39. Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. WO098610; 2011
40. Supuran C, Dedhar S, McDonald P, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO021963; 2012
41. Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO070024; 2012
42. Masereel B, Frederick R, Supuran CT. Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders. WO175654; 2012
43. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
44. Bootorabi F, Jänis J, Hytonen VP, et al. Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases. J Enzyme Inhib Med Chem 2011;26:862-70
45. Liu F, Martin-Mingot A, Lecornué F, et al. Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J Enzyme Inhib Med Chem 2012;27:886-91
46. Cavdar H, Ekinci D, Talaz O, et al. a-Carbonic anhydrases are sulfatases with cyclic diol monosulfate esters. J Enzyme Inhib Med Chem 2012;27:148-54
47. Kazancoglu EA, Güney M, Sentürk M, et al. Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity. J Enzyme Inhib Med Chem 2012;27:880-5
48. Alp C, Ozsoy S, Alp NA, et al. Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI. J Enzyme Inhib Med Chem 2012;27:818-24
49. Ekinci D, Kurbanoglu NI, Salamc E, et al. Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds. J Enzyme Inhib Med Chem 2012;27:845-8
50. Ekinci D, Al-Rashida M, Abbas G, et al. Chromone containing sulfonamides as potent carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:744-7
51. Singh S, Supuran CT. QSARs on human carbonic anhydrase VA and VB inhibitors of some new not yet synthesized, substituted aromatic/heterocyclic sulphonamides as anti-obesity agent. J Enzyme Inhib Med Chem 2012;27:666-72
52. Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem 2012;55:10742-8
53. Capasso C, De Luca V, Carginale V, et al. Biochemical properties of a novel and highly thermostable bacterial alpha-carbonic anhydrase from Sulfurihydrogenibium yellowstonense YO3AOP. J Enzyme Inhib Med Chem 2012;27:892-7
54. De Luca V, Vullo D, Scozzafava A, et al. Anion inhibition studies of an alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP. Bioorg Med Chem Lett 2012;22:5630-4
55. Vullo D, De Luca V, Scozzafava A, et al. The first activation study of a bacterial carbonic anhydrase (CA). The thermostable alpha-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. Bioorg Med Chem Lett 2012;22:6324-7
56. Vullo D, De Luca V, Scozzafava A, et al. Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense. Bioorg Med Chem Lett 2012;22:7142-5
57. Friedenwald JS. The formation of the intraocular fluid. Am J Ophthalmol 1949;32:9-27
58. Kinsey VE. Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eye. Arch Ophthalmol 1953;50:401-17
59. Kinsey VE, Barany E. The rate flow of aqueous humor. II. Derivation of rate of flow and its physiologic significance. Am J Ophthalmol 1949;32:189-202
60. Wistrand PJ. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand 1951;24:144-8
61. Becker B. The mechanism of the fall in intraocular pressure by the carbonic anhydrase inhibitor Diamox. Am J Ophthalmol 1955;39:177-83
62. Kinsey VE, Reddy DVN. Turnover of total carbon dioxide in aqueous humors and the effect thereon of acetazolamide. Arch Ophthalmol 1959;62:78-83
63. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Top Med Chem 2007;7:849-54
64. Maren TH. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967;47:595-781
65. Liao SY, Ivanov S, Ivanova A, et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet 2003;40:257-61
66. Miller WH, Dessert AM, Roblin RO. Jr. Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc 1950;72:4893-6
67. Supuran CT, Scozzafava A, Casini A. Development of sulfonamide carbonic anhydrase inhibitors (CAIs). In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase-its inhibitors and activators. CRC Press, Boca Raton (FL); 2004 p. 67-147
68. Maren TH, Jankowska L, Sanyal G, et al. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 1983;36:457-80
69. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progr Ret Eye Res 2000;19:87-112
70. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:45-9
71. Silver LH. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide dose-response study group. Surv Ophthalmol 2000;44(Suppl 2):147-53
72. Aalto-Korte K. Contact allergy to dorzolamide eye drops. Contact Dermat 1998;39:206
73. Carlsen J, Durcan J, Swartz M, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999;117:1087-8
74. Thoe Schwartzenberg GW, Trop GE. Anorexia, depression and dementia induced by dorzolamide eye drops (Trusopt). Can J Ophthalmol 1999;34:93-4
75. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403-6
76. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999;42:2641-50
77. Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long lasting-intraocular pressure lowering properties via the topical route. J Med Chem 1999;42:3690-700
78. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J Med Chem 2000;43:4542-51
79. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long lasting, topical intraocular pressure lowering properties. J Med Chem 2002;45:1466-76
80. Chiroli V, Batugo MR, Biondi S, et al. Synthesis of novel nitric oxide (NO)-releasing esters of timolol. Bioorg Med Chem Lett 2009;19:2785-8
81. Steele RM, Batugo MR, Benedini F, et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2009;19:6565-70 .
82. Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216-21
83. Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138-47
84. Benedini F, Biondi S, Ongini E. Carbonic anhydrase inhibitors derivatives. WO075155; 2008
85. Patterson B, Rui E. Thieno[3,2-e][1,2] thiazine derivative as inhibitor of carbonic anhydrase. WO120099; 2008
86. Huang Q, Rui E. Inhibitors of carbonic anhydrase. WO007814; 2009
87. Long DD, Frieman B, Hegde SS, et al. A Multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939-43
88. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165-80
89. Nair SK, Rui EY. Tricyclic inhibitors of carbonic anhydrase. WO075148; 2008
90. Schoen U, Waldeck H, Reinecker U, et al. Novel sulfamate compounds for medical use. WO050252; 2009
91. Antel J, Waldeck H, Schoen U, et al. N-Sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof. US0117823; 2007
92. Antel J, Waldeck H, Schoen U, et al. N-Sulfamoyl-N'-benzopyranpiperidines as inhibitors of carbonic anhydrases. WO054580; 2007
93. Matulis D, Dudutiene V, Matuliene J, et al. Benzimidazo[1,2-c][1,2,3] thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof. WO016288; 2008
94. Baranauskiene L, Hilvo M, Matuliene J, et al. Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c] [1,2,3] thiadiazole-7-sulphonamides. J Enzyme Inhib Med Chem 2010;25:863-70
95. Gant TG. Sulfonamide inhibitors of carbonic anhydrase II. US0125067; 2010
96. Rao T, Zhang C. Sulfonamide inhibitors of carbonic anhydrase. US0317655; 2010
97. Chang JN, Hughes PM, Devries GW. Carbonic anhydrase inhibitor sustained release intraocular drug delivery system. US0034448; 2011
98. Inoue J, Shah T. Ophthalmic composition. WO140194; 2011
99. Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511-22
100. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62
101. Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335-44
102. Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271-7
103. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Cambridge) 2012;48:1868-70
104. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55:1721-30
105. Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 2012;22:859-62
106. Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:407-11
107. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-Ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474-8
108. Molnar F, Siguero R, Sato Y, et al. 1alpha,25(OH)2-3-Epi-Vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor. PLoS One 2011;6:e18124
109. Kutuzova G, Gabelt BAT, Kiland JA, et al. 1alpha,25-Dihydroxyvitamin D3 and its analog, 2-methylene-19-nor (20S)-1a,25-dihydroxyvitamin D3 (2MD), suppress intraocular pressure in non-human primates. Arch Biochem Biophys 2012;518:53-60